Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gentian Diagnostics ASA ( (DE:6FK) ) has issued an announcement.
Gentian Diagnostics ASA reports continued solid progress in developing its turbidimetric NT-proBNP assay, its top pipeline project, with improvements in analytical performance driven by refinement of the calibration approach. To secure a more robust, high-quality product, the company has chosen to carry out additional refinement work before introducing a research-use-only version, causing a minor delay, but it still expects to update the market on the RUO product in the first quarter of 2026 and remains on track to launch a CE-marked NT-proBNP assay in the fourth quarter of 2026, in line with earlier guidance.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a fast-growing Norwegian developer and manufacturer of diagnostic tests, focusing on turbidimetric assays for use in clinical laboratories. The company’s pipeline includes high-priority cardiac biomarkers such as its NT-proBNP assay, aimed at strengthening its position in the global in vitro diagnostics market.
Average Trading Volume: 12,744
Current Market Cap: NOK900.7M
Learn more about 6FK stock on TipRanks’ Stock Analysis page.